CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [68Ga]Ga-Pentixafor /[177Lu]Lu-Pentixather

• DOI: 10.1007/s00259-021-05196-4
• Publication Date: 2021-02-09T03:04:50Z
• Authors: Sarah M. Jacobs; Pieter Wesseling; Bart de Keizer; Nelleke Tolboom; F. F. Tessa Ververs; Gerard C. Krijger; Bart A. Westerman; Tom J. Snijders; Pierre A. Robe; Anja G. van der Kolk
• Keywords: Tissue microarray

Abstract Purpose CXCR4 (over)expression is found in multiple human cancer types, while expression low or absent healthy tissue. In glioblastoma it associated with a poor prognosis and more extensive infiltrative phenotype. can be targeted by the diagnostic PET agent [ 68 Ga]Ga-Pentixafor its therapeutic counterpart 177 Lu]Lu-Pentixather. We aimed to investigate of tissue further examine potential these agents. Methods mRNA was examined using R2 genomics platform. Glioblastoma cores were stained for CXCR4. staining tumor cells scored. Stained components (cytoplasm and/or nuclei blood vessels) documented. Clinical characteristics information on IDH MGMT promoter methylation status collected. Seven pilot patients recurrent underwent PET; residual resected Results Two large datasets ( N = 284; 540) assesed. Of 191 glioblastomas, 426 analyzed immunohistochemistry. Seventy-eight (23 tumors) negative, 18 (5 had both strong staining. The remaining 330 (163 showed inter- intra-tumor variation expression; also seen seven patients—not directly translatable results. Both immunohistochemical analysis negative normal brain no significant correlation between survival. Conclusion Using immunohistochemistry, high subset glioblastomas as well variation. Caution should exercised translating ex vivo uptake. However, when identified Ga]Ga-Pentixafor, might good candidates radionuclide therapy Lu]Lu-Pentixather future.